Loading clinical trials...

UNKNOWNNA

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

NCT03848390•The University of Texas Health Science Center, Houston

Summary

The purpose of the study is to examine the effects of modified time-restricted feeding and conventional dietary approaches in motivated obese fatty liver patients on biochemical markers, imaging studies, and anthropometric measurements.

Eligibility

Age

8 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Motivated obese fatty liver patients aged 8 -18yrs with ALT \>80

Exclusion Criteria

•Patients with metabolic disorders,
•On certain medications (i.e., amiodarone, corticosteroids, methotrexate, select antipsychotics /antidepressants, HAART, valproic acid),
•Kwashiorkor
•Alcohol abuse,
•Rapid surgical weight loss,
•History of parenteral nutrition and
•Hepatitis C.

Locations (1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States

Key Dates

Start Date

April 1, 2019

Primary Completion Date

April 30, 2020

Completion Date

April 30, 2020

Last Updated

March 15, 2019

Enrollment

ESTIMATED participants

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

Conventional diet

BEHAVIORAL

Modified Time-restricted Feeding

BEHAVIORAL

Physical activity

BEHAVIORAL

Restricted consumption of sweetened beverages

BEHAVIORAL

Contacts

Essam M Imseis, MD

CONTACT

713-500-5663 essam.imseis@uth.tmc.edu

Identification of Liver Fibrosis Biomarkers

NCT06819917

Non-alcoholic Fatty LiverNon-Alcoholic Fatty Liver Disease+1 more

View study

RECRUITINGPHASE3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227

Non-alcoholic Fatty Liver Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 15, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

Inclusion Criteria

Exclusion Criteria

Identification of Liver Fibrosis Biomarkers

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients

Nonalcoholic Steatohepatitis in Chinese Children

OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities